Solid cancer: the new tumour spread endpoint opens novel opportunities

Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced ima...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Michael, Rosel, Daniel, Brábek, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889500/
https://www.ncbi.nlm.nih.gov/pubmed/31427682
http://dx.doi.org/10.1038/s41416-019-0536-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889500/
https://www.ncbi.nlm.nih.gov/pubmed/31427682
http://dx.doi.org/10.1038/s41416-019-0536-0

Ejemplares similares